02177nas a2200421   4500000000100000008004100001260001900042653001800061653001500079653001000094653000900104653004500113653002000158653001400178653002200192653001100214653001400225653002000239653001100259653001200270653002900282653001900311653000900330653001600339653002700355653001700382653001600399653002000415653002800435100001300463700001100476700001400487245009700501300001100598490000600609520112600615022001401741       1978                            d  c1978 Dec 23-3010aAcute disease10aAdolescent10aAdult10aAged10aAngiotensin-Converting Enzyme Inhibitors10aChronic Disease10aEnteritis10aEnzyme Inhibitors10aFemale10aGranuloma10aHodgkin Disease10aHumans10aleprosy10aLiver Cirrhosis, Biliary10aLiver Diseases10aMale10aMiddle Aged10aPeptidyl-Dipeptidase A10aPrednisolone10aSarcoidosis10aschistosomiasis10aTuberculosis, Pulmonary1 aStuddy P1 aBird R1 aJAMES D G00aSerum angiotensin-converting enzyme (SACE) in sarcoidosis and other granulomatous disorders.  a1331-40 v23 a<p>Serum angiotensin-converting enzyme (SACE) activity was significantly higher in 90 patients with sarcoidosis (55 +/- [S.D.] 23 nmol min-1 ml-1) than in 80 healthy controls (34 +/- 9 nmol min-1 ml-1). Steroid therapy modified SACE activity; 60 sarcoidosis patients who were not being treated with steroids had significantly higher enzyme activities (58 +/- 24 nmol min-1 ml-1) than 30 steroid-treated sarcoidosis patients (40 +/- 19 nmol min-1 ml-1). In 50% of the non-steroid treated sarcoidosis patients SACE activity was more than 2 S.D. above the mean value for the controls. SACE activity was measured in 22 tuberculous patients (38 +/- 14 nmol min-1 ml-1), 20 leprosy patients (34 +/- 9 nmol min-1 ml-1), 31 with primary biliary cirrhosis (44 +/- 20 nmol min-1 ml-1), 26 with inflammatory bowel disease (31 +/- 9 nmol min-1 ml-1), 8 with hepatic granulomatous disease, 5 with Hodgkin's disease, and 2 with schistosomiasis. The combined false-positive rate for these non-sarcoidosis patients was 10%. Serial SACE assays provide useful information on the course of sarcoidosis and response to steroid treatment.</p>  a0140-6736